1. Home
  2. LSAK vs GOSS Comparison

LSAK vs GOSS Comparison

Compare LSAK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • GOSS
  • Stock Information
  • Founded
  • LSAK 1997
  • GOSS 2015
  • Country
  • LSAK South Africa
  • GOSS United States
  • Employees
  • LSAK N/A
  • GOSS N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSAK Finance
  • GOSS Health Care
  • Exchange
  • LSAK Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • LSAK 344.5M
  • GOSS 586.6M
  • IPO Year
  • LSAK N/A
  • GOSS 2019
  • Fundamental
  • Price
  • LSAK $4.61
  • GOSS $2.94
  • Analyst Decision
  • LSAK
  • GOSS Strong Buy
  • Analyst Count
  • LSAK 0
  • GOSS 4
  • Target Price
  • LSAK N/A
  • GOSS $8.50
  • AVG Volume (30 Days)
  • LSAK 17.0K
  • GOSS 3.3M
  • Earning Date
  • LSAK 11-05-2025
  • GOSS 11-06-2025
  • Dividend Yield
  • LSAK N/A
  • GOSS N/A
  • EPS Growth
  • LSAK N/A
  • GOSS N/A
  • EPS
  • LSAK N/A
  • GOSS N/A
  • Revenue
  • LSAK $574,080,000.00
  • GOSS $40,237,000.00
  • Revenue This Year
  • LSAK $1.06
  • GOSS N/A
  • Revenue Next Year
  • LSAK $13.32
  • GOSS $30.65
  • P/E Ratio
  • LSAK N/A
  • GOSS N/A
  • Revenue Growth
  • LSAK 4.13
  • GOSS N/A
  • 52 Week Low
  • LSAK $3.39
  • GOSS $0.66
  • 52 Week High
  • LSAK $5.60
  • GOSS $2.98
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 47.41
  • GOSS 76.74
  • Support Level
  • LSAK $4.50
  • GOSS $2.41
  • Resistance Level
  • LSAK $4.76
  • GOSS $2.71
  • Average True Range (ATR)
  • LSAK 0.13
  • GOSS 0.19
  • MACD
  • LSAK -0.02
  • GOSS 0.04
  • Stochastic Oscillator
  • LSAK 24.49
  • GOSS 96.37

About LSAK Lesaka Technologies Inc.

Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: